Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the ...
A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.
HealthDay News — In middle-aged and older adults, anticholinergic drug burden is associated with an increased risk for ...
Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.
From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.
Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.
New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 ...
Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.
Supplementation does not change four-week cumulative incidence of health care utilization among adults with newly diagnosed COVID-19.
Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.
The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...
Sotyktu’s approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results